Schrödinger, Inc. (NASDAQ:SDGR) Receives $32.29 Consensus PT from Brokerages

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have received a consensus rating of “Buy” from the eight analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $32.29.

Several analysts recently issued reports on the company. Piper Sandler cut their price objective on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. KeyCorp increased their price objective on Schrödinger from $25.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Finally, BMO Capital Markets increased their price objective on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th.

Schrödinger Stock Down 0.1 %

Shares of Schrödinger stock opened at $21.02 on Friday. The stock has a market cap of $1.53 billion, a PE ratio of -8.98 and a beta of 1.62. The business has a fifty day simple moving average of $22.48 and a 200-day simple moving average of $20.64. Schrödinger has a 12 month low of $16.67 and a 12 month high of $29.15.

Schrödinger (NASDAQ:SDGR) last issued its earnings results on Wednesday, February 26th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). The business had revenue of $88.32 million during the quarter, compared to analyst estimates of $83.20 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Analysts expect that Schrödinger will post -2.37 EPS for the current fiscal year.

Insider Buying and Selling at Schrödinger

In other Schrödinger news, CFO Geoffrey Craig Porges sold 5,491 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the transaction, the chief financial officer now directly owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Schrödinger

Institutional investors have recently bought and sold shares of the stock. Private Advisor Group LLC increased its stake in shares of Schrödinger by 20.5% in the third quarter. Private Advisor Group LLC now owns 12,150 shares of the company’s stock worth $225,000 after purchasing an additional 2,065 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of Schrödinger by 5.0% in the third quarter. Harbor Capital Advisors Inc. now owns 13,059 shares of the company’s stock worth $242,000 after purchasing an additional 622 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Schrödinger by 1.4% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock worth $40,644,000 after purchasing an additional 29,920 shares during the period. Pier 88 Investment Partners LLC increased its stake in shares of Schrödinger by 83.6% in the third quarter. Pier 88 Investment Partners LLC now owns 77,130 shares of the company’s stock worth $1,431,000 after purchasing an additional 35,120 shares during the period. Finally, KBC Group NV increased its stake in shares of Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company’s stock worth $47,000 after purchasing an additional 783 shares during the period. 79.05% of the stock is currently owned by institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.